MIM
QTTB icon

MetLife Investment Management’s Q32 Bio QTTB Stock Holding History

MetLife Investment Management’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,563
Closed -$159K – 2867
2024
Q3 		$159K Buy
+3,563
New +$131K ﹤0.01% 2405
2021
Q4 		– Sell
-874
Closed -$124K – 2561
2021
Q3 		$124K Buy
+874
New +$111K ﹤0.01% 2345
2021
Q2 		– Sell
-178
Closed -$30.2K – 2495
2021
Q1 		$30.2K Sell
178
-706
-80% -$149K ﹤0.01% 2294
2020
Q4 		$180K Hold
884
– – ﹤0.01% 2033
2020
Q3 		$170K Hold
884
– – ﹤0.01% 1952
2020
Q2 		$242K Buy
884
+218
+33% +$58.1K ﹤0.01% 1789
2020
Q1 		$186K Hold
666
– – ﹤0.01% 1741
2019
Q4 		$248K Hold
666
– – ﹤0.01% 1856
2019
Q3 		$217K Hold
666
– – ﹤0.01% 1901
2019
Q2 		$235K Buy
666
+198
+42% +$77.8K ﹤0.01% 1933
2019
Q1 		$234K Hold
468
– – ﹤0.01% 1899
2018
Q4 		$188K Buy
+468
New +$177K ﹤0.01% 1943

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

MetLife Investment Management's QTTB Position: Q4 2024 in Review

MetLife Investment Management sold out of Q32 Bio (QTTB) in Q4 2024, closing a stake of 3,563 shares — an estimated $159K sold.

MetLife Investment Management first reported a position in QTTB in Q4 2018 and held it in 12 quarters. The position peaked at $248K in Q4 2019. 92 funds tracked by Wall St. Rank hold QTTB as of Q4 2024.

  • MetLife Investment Management reported no remaining Q32 Bio position as of Q4 2024 after selling out during the quarter.
  • MetLife Investment Management sold 3,563 Q32 Bio shares in Q4 2024, an estimated $159K.
  • MetLife Investment Management first reported a position in Q32 Bio in Q4 2018 and held it in 12 quarters.
  • MetLife Investment Management's Q32 Bio position peaked at $248K in Q4 2019.
  • 92 funds tracked by Wall St. Rank held Q32 Bio as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.